Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
The relevant question is no longer whether Indonesia should have signed the ART. It is what Indonesia does with the leverage it still holds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results